Functional significance of erythropoietin in renal cell carcinoma
Open Access
- 10 January 2013
- journal article
- review article
- Published by Springer Nature in BMC Cancer
- Vol. 13 (1) , 1-7
Abstract
One of the molecules regulated by the transcription factor, hypoxia inducible factor (HIF), is the hypoxia-responsive hematopoietic factor, erythropoietin (EPO). This may have relevance to the development of renal cell carcinoma (RCC), where mutations of the von Hippel-Lindau (VHL) gene are major risk factors for the development of familial and sporadic RCC. VHL mutations up-regulate and stabilize HIF, which in turn activates many downstream molecules, including EPO, that are known to promote angiogenesis, drug resistance, proliferation and progression of solid tumours. HIFs typically respond to hypoxic cellular environment. While the hypoxic microenvironment plays a critical role in the development and progression of tumours in general, it is of special significance in the case of RCC because of the link between VHL, HIF and EPO. EPO and its receptor, EPOR, are expressed in many cancers, including RCC. This limits the use of recombinant human EPO (rhEPO) to treat anaemia in cancer patients, because the rhEPO may be stimulatory to the cancer. EPO may also stimulate epithelial-mesenchymal transition (EMT) in RCC, and pathological EMT has a key role in cancer progression. In this mini review, we summarize the current knowledge of the role of EPO in RCC. The available data, either for or against the use of EPO in RCC patients, are equivocal and insufficient to draw a definitive conclusion.Keywords
This publication has 105 references indexed in Scilit:
- Erythropoietin, erythropoiesis and beyondBiochemical Pharmacology, 2011
- The PI3K/Akt/mTOR pathway mediates retinal progenitor cell survival under hypoxic and superoxide stressMolecular and Cellular Neuroscience, 2011
- VHL and HIF signalling in renal cell carcinogenesisThe Journal of Pathology, 2010
- The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapyKidney International, 2009
- Association of Abnormal Preoperative Laboratory Values with Survival After Radical Nephrectomy for Clinically Confined Clear Cell Renal Cell CarcinomaUrology, 2008
- Novel somatic mutations of theVHL gene in an erythropoietin-producing renal carcinoma associated with secondary polycythemia and elevated circulating endothelial progenitor cellsAmerican Journal of Hematology, 2008
- Does inhibition of degradation of hypoxia‐inducible factor (HIF) α always lead to activation of HIF? lessons learnt from the effect of proteasomal inhibition on HIF activityJournal of Cellular Biochemistry, 2007
- Erythropoietin gene expression in renal carcinoma is considerably more frequent than paraneoplastic polycythemiaInternational Journal of Cancer, 2007
- Renal Cell CarcinomaJAMA, 2004
- Von Hippel–Lindau disease maps to the region of chromosome 3 associated with renal cell carcinomaNature, 1988